Poly Medicure Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: April 25, 2025, 9:42 pm

Market Cap	25,680 Cr.
Current Price	2,535
High / Low	3,358/1,563
Stock P/E	81.5
Book Value	256
Dividend Yield	0.12 %
ROCE	23.6 %
ROE	19.1 %
Face Value	5.00
PEG Ratio	4.63

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Poly Medicure Ltd

Competitors of Poly Medicure Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Constronics Infra Ltd	82.7 Cr.	66.0	158/50.6	30.0	22.9	0.00 %	20.8 %	118 %	10.0
Centenial Surgical Suture Ltd	47.9 Cr.	131	170/82.2		89.5	0.00 %	8.07 %	3.57 %	10.0
Adeshwar Meditex Ltd	23.1 Cr.	16.0	30.0/15.0	10.6	24.8	0.00 %	9.62 %	5.93 %	10.0
Poly Medicure Ltd	25,680 Cr.	2,535	3,358/1,563	81.5	256	0.12 %	23.6 %	19.1 %	5.00
Mohini Health & Hygiene Ltd	107 Cr.	58.5	86.9/46.0	10.2	57.2	0.85 %	14.5 %	11.1 %	10.0
Industry Average	12,893.50 Cr	561.30		33.08	90.08	0.19%	15.32%	31.54%	9.00

All Competitor Stocks of Poly Medicure Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	230	258	249	275	285	307	321	337	340	378	385	420	424
Expenses	179	202	202	210	214	224	234	253	249	281	281	305	310
Operating Profit	51	56	46	65	71	83	87	84	90	97	104	115	115
OPM %	22%	22%	19%	24%	25%	27%	27%	25%	27%	26%	27%	27%	27%
Other Income	8	8	5	9	15	9	14	15	17	15	17	27	24
Interest	-1	1	1	0	5	2	2	2	3	3	3	3	3
Depreciation	14	14	14	14	14	15	16	16	16	16	20	21	22
Profit before tax	46	49	36	59	67	75	83	81	88	92	98	118	113
Tax %	25%	26%	26%	27%	25%	22%	24%	23%	26%	26%	25%	26%	25%
Net Profit	35	36	27	44	50	59	63	62	65	68	74	87	85
EPS in Rs	3.60	3.77	2.81	4.54	5.21	6.13	6.54	6.48	6.78	7.12	7.71	8.63	8.41

Last Updated: February 28, 2025, 5:50 pm

Below is a detailed analysis of the quarterly data for Poly Medicure Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is 424.00 Cr.. The value appears strong and on an upward trend. It has increased from 420.00 Cr. (Sep 2024) to 424.00 Cr., marking an increase of 4.00 Cr..
For Expenses, as of Dec 2024, the value is 310.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 305.00 Cr. (Sep 2024) to 310.00 Cr., marking an increase of 5.00 Cr..
For Operating Profit, as of Dec 2024, the value is 115.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 115.00 Cr..
For OPM %, as of Dec 2024, the value is 27.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 27.00%.
For Other Income, as of Dec 2024, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 27.00 Cr. (Sep 2024) to 24.00 Cr., marking a decrease of 3.00 Cr..
For Interest, as of Dec 2024, the value is 3.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 3.00 Cr..
For Depreciation, as of Dec 2024, the value is 22.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 21.00 Cr. (Sep 2024) to 22.00 Cr., marking an increase of 1.00 Cr..
For Profit before tax, as of Dec 2024, the value is 113.00 Cr.. The value appears to be declining and may need further review. It has decreased from 118.00 Cr. (Sep 2024) to 113.00 Cr., marking a decrease of 5.00 Cr..
For Tax %, as of Dec 2024, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Sep 2024) to 25.00%, marking a decrease of 1.00%.
For Net Profit, as of Dec 2024, the value is 85.00 Cr.. The value appears to be declining and may need further review. It has decreased from 87.00 Cr. (Sep 2024) to 85.00 Cr., marking a decrease of 2.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 8.41. The value appears to be declining and may need further review. It has decreased from 8.63 (Sep 2024) to 8.41, marking a decrease of 0.22.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:12 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	259	322	390	411	454	519	610	687	785	922	1,115	1,375	1,607
Expenses	206	246	304	323	361	397	479	520	569	707	847	1,013	1,177
Operating Profit	53	76	86	88	93	122	131	166	216	215	267	362	430
OPM %	20%	24%	22%	21%	21%	23%	22%	24%	28%	23%	24%	26%	27%
Other Income	0	11	28	8	14	16	20	21	22	40	38	60	83
Interest	7	9	10	10	8	12	14	20	11	6	11	14	13
Depreciation	13	14	19	21	24	29	37	41	48	54	57	64	78
Profit before tax	33	63	85	65	75	97	100	126	180	195	237	344	422
Tax %	30%	30%	27%	27%	27%	27%	35%	24%	25%	25%	25%	25%
Net Profit	24	45	62	48	55	71	65	96	136	147	179	258	315
EPS in Rs	2.75	5.11	7.07	5.47	6.25	8.00	7.41	10.86	14.17	15.28	18.69	26.91	31.87
Dividend Payout %	9%	20%	18%	27%	40%	25%	27%	18%	18%	16%	16%	11%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	87.50%	37.78%	-22.58%	14.58%	29.09%	-8.45%	47.69%	41.67%	8.09%	21.77%	44.13%
Change in YoY Net Profit Growth (%)	0.00%	-49.72%	-60.36%	37.16%	14.51%	-37.54%	56.14%	-6.03%	-33.58%	13.68%	22.37%

Poly Medicure Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	16%
5 Years:	18%
3 Years:	21%
TTM:	23%

Compounded Profit Growth
10 Years:	21%
5 Years:	32%
3 Years:	24%
TTM:	27%

Stock Price CAGR
10 Years:	26%
5 Years:	64%
3 Years:	41%
1 Year:	60%

Return on Equity
10 Years:	18%
5 Years:	17%
3 Years:	16%
Last Year:	19%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 7:52 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	11	22	22	22	44	44	44	44	48	48	48	48	51
Reserves	101	124	174	207	227	294	337	391	918	1,040	1,194	1,422	2,541
Borrowings	49	67	79	82	101	133	161	207	137	127	149	174	161
Other Liabilities	53	73	89	76	85	94	112	126	121	163	187	214	300
Total Liabilities	214	286	364	387	457	565	654	767	1,224	1,377	1,577	1,859	3,052
Fixed Assets	92	123	165	182	207	265	306	363	426	488	635	867	972
CWIP	8	20	10	14	20	18	19	25	21	43	78	76	62
Investments	4	3	4	4	3	17	8	25	354	346	132	167	1,090
Other Assets	110	140	185	187	227	264	321	354	422	499	732	748	928
Total Assets	214	286	364	387	457	565	654	767	1,224	1,377	1,577	1,859	3,052

Below is a detailed analysis of the balance sheet data for Poly Medicure Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹51.00 Cr.. The value appears strong and on an upward trend. It has increased from 48.00 Cr. (Mar 2024) to ₹51.00 Cr., marking an increase of 3.00 Cr..
For Reserves, as of Sep 2024, the value is ₹2,541.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,422.00 Cr. (Mar 2024) to ₹2,541.00 Cr., marking an increase of 1,119.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹161.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 174.00 Cr. (Mar 2024) to ₹161.00 Cr., marking a decrease of 13.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹300.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 214.00 Cr. (Mar 2024) to ₹300.00 Cr., marking an increase of 86.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹3,052.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,859.00 Cr. (Mar 2024) to ₹3,052.00 Cr., marking an increase of 1,193.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹972.00 Cr.. The value appears strong and on an upward trend. It has increased from 867.00 Cr. (Mar 2024) to ₹972.00 Cr., marking an increase of 105.00 Cr..
For CWIP, as of Sep 2024, the value is ₹62.00 Cr.. The value appears to be declining and may need further review. It has decreased from 76.00 Cr. (Mar 2024) to ₹62.00 Cr., marking a decrease of 14.00 Cr..
For Investments, as of Sep 2024, the value is ₹1,090.00 Cr.. The value appears strong and on an upward trend. It has increased from 167.00 Cr. (Mar 2024) to ₹1,090.00 Cr., marking an increase of 923.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹928.00 Cr.. The value appears strong and on an upward trend. It has increased from 748.00 Cr. (Mar 2024) to ₹928.00 Cr., marking an increase of 180.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹3,052.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,859.00 Cr. (Mar 2024) to ₹3,052.00 Cr., marking an increase of 1,193.00 Cr..

Notably, the Reserves (2,541.00 Cr.) exceed the Borrowings (161.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	39	66	63	63	56	75	106	128	119	123	191	266
Cash from Investing Activity +	-31	-58	-59	-31	-56	-88	-101	-107	-436	-85	-179	-241
Cash from Financing Activity +	-8	5	-6	-31	-0	16	-5	-21	317	-35	-13	-20
Net Cash Flow	0	13	-2	1	0	3	1	1	0	3	-1	5

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	4.00	9.00	7.00	6.00	-8.00	-11.00	-30.00	-41.00	79.00	88.00	118.00	188.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	61	52	59	74	77	79	77	68	72	82	77	72
Inventory Days	149	142	148	114	194	161	186	241	217	218	237	167
Days Payable	99	101	101	76	131	96	123	142	111	115	105	72
Cash Conversion Cycle	111	94	106	111	140	144	139	166	179	185	209	166
Working Capital Days	56	31	45	65	81	94	83	73	107	116	112	136
ROCE %	27%	33%	30%	26%	24%	26%	22%	25%	22%	17%	18%	23%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	44.66%	53.34%	53.33%	53.33%	53.32%	53.32%	53.17%	53.17%	53.14%	66.02%	62.56%	62.44%
FIIs	15.07%	15.59%	16.27%	16.33%	16.21%	15.61%	14.49%	14.10%	12.37%	9.91%	11.88%	12.33%
DIIs	3.33%	3.25%	3.39%	3.38%	3.67%	4.25%	5.15%	5.46%	7.21%	9.34%	12.33%	11.66%
Public	36.94%	27.82%	27.02%	26.97%	26.79%	26.82%	27.20%	27.28%	27.25%	14.72%	13.23%	13.57%
No. of Shareholders	33,831	33,296	34,239	32,015	35,393	36,141	34,649	36,053	36,712	36,852	38,352	60,686

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
UTI Flexi Cap Fund	2,144,773	1.24	312.42	2,144,773	2025-04-22 16:11:32	0%
Quant Small Cap Fund	1,043,752	0.97	152.04	1,043,752	2025-04-22 16:11:32	0%
UTI Unit Linked Insurance Plan (ULIP) - Fifteen Year Plan	180,609	0.5	26.31	180,609	2025-04-22 07:46:55	0%
UTI Unit Linked Insurance Plan (ULIP) - Ten Year Plan	180,609	0.5	26.31	180,609	2025-04-22 05:20:40	0%
WhiteOak Capital Flexi Cap Fund	140,638	0.69	20.49	140,638	2025-04-22 15:56:54	0%
Bank of India Small Cap Fund	96,500	1.54	14.06	96,500	2025-04-22 15:56:54	0%
UTI Healthcare Fund	62,328	0.99	9.08	62,328	2025-04-22 15:56:54	0%
WhiteOak Capital Mid Cap Fund	51,906	0.49	7.56	51,906	2025-04-22 15:56:54	0%
Bank of India ELSS Tax Saver	49,768	0.66	7.25	49,768	2025-04-22 16:11:32	0%
Bank of India ELSS Tax Saver - Eco Plan	49,768	0.66	7.25	49,768	2025-04-22 15:56:54	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	5.00	5.00	5.00	5.00	5.00
Basic EPS (Rs.)	26.92	18.69	15.28	15.25	10.86
Diluted EPS (Rs.)	26.90	18.67	15.27	15.24	10.86
Cash EPS (Rs.)	33.31	24.44	20.65	18.78	15.21
Book Value[Excl.RevalReserv]/Share (Rs.)	153.18	129.41	113.40	100.71	49.27
Book Value[Incl.RevalReserv]/Share (Rs.)	153.18	129.41	113.40	100.71	49.27
Revenue From Operations / Share (Rs.)	143.35	116.24	96.25	82.03	77.88
PBDIT / Share (Rs.)	43.45	31.43	26.17	24.28	20.67
PBIT / Share (Rs.)	36.79	25.47	20.55	19.32	16.08
PBT / Share (Rs.)	35.61	24.55	20.10	18.43	14.00
Net Profit / Share (Rs.)	26.65	18.48	15.02	13.83	10.62
NP After MI And SOA / Share (Rs.)	26.91	18.69	15.28	14.17	10.86
PBDIT Margin (%)	30.30	27.04	27.19	29.59	26.54
PBIT Margin (%)	25.66	21.91	21.34	23.55	20.64
PBT Margin (%)	24.83	21.12	20.88	22.47	17.98
Net Profit Margin (%)	18.58	15.90	15.60	16.85	13.63
NP After MI And SOA Margin (%)	18.77	16.07	15.87	17.27	13.95
Return on Networth / Equity (%)	17.56	14.43	13.47	14.07	22.04
Return on Capital Employeed (%)	23.42	19.03	17.13	17.60	24.88
Return On Assets (%)	13.89	11.36	10.64	11.10	12.49
Long Term Debt / Equity (X)	0.00	0.01	0.03	0.06	0.25
Total Debt / Equity (X)	0.11	0.11	0.11	0.10	0.38
Asset Turnover Ratio (%)	0.80	0.73	0.68	0.76	0.92
Current Ratio (X)	2.40	2.75	3.46	4.12	1.61
Quick Ratio (X)	1.77	2.04	2.71	3.38	1.04
Inventory Turnover Ratio (X)	2.16	2.25	2.39	2.22	2.24
Dividend Payout Ratio (NP) (%)	11.14	13.37	16.36	0.00	18.40
Dividend Payout Ratio (CP) (%)	8.93	10.14	11.95	0.00	12.93
Earning Retention Ratio (%)	88.86	86.63	83.64	0.00	81.60
Cash Earning Retention Ratio (%)	91.07	89.86	88.05	0.00	87.07
Interest Coverage Ratio (X)	36.90	34.12	58.99	27.35	9.96
Interest Coverage Ratio (Post Tax) (X)	23.63	21.07	34.86	16.57	6.12
Enterprise Value (Cr.)	15271.32	9107.85	9208.87	7911.73	2221.33
EV / Net Operating Revenue (X)	11.10	8.17	9.98	10.06	3.23
EV / EBITDA (X)	36.62	30.20	36.69	33.99	12.18
MarketCap / Net Operating Revenue (X)	11.08	8.20	9.86	9.97	3.03
Retention Ratios (%)	88.85	86.62	83.63	0.00	81.59
Price / BV (X)	10.37	7.36	8.37	8.12	4.78
Price / Net Operating Revenue (X)	11.08	8.20	9.86	9.97	3.03
EarningsYield	0.01	0.01	0.01	0.01	0.04

After reviewing the key financial ratios for Poly Medicure Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 5.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 5.00.
For Basic EPS (Rs.), as of Mar 24, the value is 26.92. This value is within the healthy range. It has increased from 18.69 (Mar 23) to 26.92, marking an increase of 8.23.
For Diluted EPS (Rs.), as of Mar 24, the value is 26.90. This value is within the healthy range. It has increased from 18.67 (Mar 23) to 26.90, marking an increase of 8.23.
For Cash EPS (Rs.), as of Mar 24, the value is 33.31. This value is within the healthy range. It has increased from 24.44 (Mar 23) to 33.31, marking an increase of 8.87.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 153.18. It has increased from 129.41 (Mar 23) to 153.18, marking an increase of 23.77.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 153.18. It has increased from 129.41 (Mar 23) to 153.18, marking an increase of 23.77.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 143.35. It has increased from 116.24 (Mar 23) to 143.35, marking an increase of 27.11.
For PBDIT / Share (Rs.), as of Mar 24, the value is 43.45. This value is within the healthy range. It has increased from 31.43 (Mar 23) to 43.45, marking an increase of 12.02.
For PBIT / Share (Rs.), as of Mar 24, the value is 36.79. This value is within the healthy range. It has increased from 25.47 (Mar 23) to 36.79, marking an increase of 11.32.
For PBT / Share (Rs.), as of Mar 24, the value is 35.61. This value is within the healthy range. It has increased from 24.55 (Mar 23) to 35.61, marking an increase of 11.06.
For Net Profit / Share (Rs.), as of Mar 24, the value is 26.65. This value is within the healthy range. It has increased from 18.48 (Mar 23) to 26.65, marking an increase of 8.17.
For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 26.91. This value is within the healthy range. It has increased from 18.69 (Mar 23) to 26.91, marking an increase of 8.22.
For PBDIT Margin (%), as of Mar 24, the value is 30.30. This value is within the healthy range. It has increased from 27.04 (Mar 23) to 30.30, marking an increase of 3.26.
For PBIT Margin (%), as of Mar 24, the value is 25.66. This value exceeds the healthy maximum of 20. It has increased from 21.91 (Mar 23) to 25.66, marking an increase of 3.75.
For PBT Margin (%), as of Mar 24, the value is 24.83. This value is within the healthy range. It has increased from 21.12 (Mar 23) to 24.83, marking an increase of 3.71.
For Net Profit Margin (%), as of Mar 24, the value is 18.58. This value exceeds the healthy maximum of 10. It has increased from 15.90 (Mar 23) to 18.58, marking an increase of 2.68.
For NP After MI And SOA Margin (%), as of Mar 24, the value is 18.77. This value is within the healthy range. It has increased from 16.07 (Mar 23) to 18.77, marking an increase of 2.70.
For Return on Networth / Equity (%), as of Mar 24, the value is 17.56. This value is within the healthy range. It has increased from 14.43 (Mar 23) to 17.56, marking an increase of 3.13.
For Return on Capital Employeed (%), as of Mar 24, the value is 23.42. This value is within the healthy range. It has increased from 19.03 (Mar 23) to 23.42, marking an increase of 4.39.
For Return On Assets (%), as of Mar 24, the value is 13.89. This value is within the healthy range. It has increased from 11.36 (Mar 23) to 13.89, marking an increase of 2.53.
For Long Term Debt / Equity (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.01 (Mar 23) to 0.00, marking a decrease of 0.01.
For Total Debt / Equity (X), as of Mar 24, the value is 0.11. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.11.
For Asset Turnover Ratio (%), as of Mar 24, the value is 0.80. It has increased from 0.73 (Mar 23) to 0.80, marking an increase of 0.07.
For Current Ratio (X), as of Mar 24, the value is 2.40. This value is within the healthy range. It has decreased from 2.75 (Mar 23) to 2.40, marking a decrease of 0.35.
For Quick Ratio (X), as of Mar 24, the value is 1.77. This value is within the healthy range. It has decreased from 2.04 (Mar 23) to 1.77, marking a decrease of 0.27.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 2.16. This value is below the healthy minimum of 4. It has decreased from 2.25 (Mar 23) to 2.16, marking a decrease of 0.09.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 11.14. This value is below the healthy minimum of 20. It has decreased from 13.37 (Mar 23) to 11.14, marking a decrease of 2.23.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 8.93. This value is below the healthy minimum of 20. It has decreased from 10.14 (Mar 23) to 8.93, marking a decrease of 1.21.
For Earning Retention Ratio (%), as of Mar 24, the value is 88.86. This value exceeds the healthy maximum of 70. It has increased from 86.63 (Mar 23) to 88.86, marking an increase of 2.23.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 91.07. This value exceeds the healthy maximum of 70. It has increased from 89.86 (Mar 23) to 91.07, marking an increase of 1.21.
For Interest Coverage Ratio (X), as of Mar 24, the value is 36.90. This value is within the healthy range. It has increased from 34.12 (Mar 23) to 36.90, marking an increase of 2.78.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 23.63. This value is within the healthy range. It has increased from 21.07 (Mar 23) to 23.63, marking an increase of 2.56.
For Enterprise Value (Cr.), as of Mar 24, the value is 15,271.32. It has increased from 9,107.85 (Mar 23) to 15,271.32, marking an increase of 6,163.47.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 11.10. This value exceeds the healthy maximum of 3. It has increased from 8.17 (Mar 23) to 11.10, marking an increase of 2.93.
For EV / EBITDA (X), as of Mar 24, the value is 36.62. This value exceeds the healthy maximum of 15. It has increased from 30.20 (Mar 23) to 36.62, marking an increase of 6.42.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 11.08. This value exceeds the healthy maximum of 3. It has increased from 8.20 (Mar 23) to 11.08, marking an increase of 2.88.
For Retention Ratios (%), as of Mar 24, the value is 88.85. This value exceeds the healthy maximum of 70. It has increased from 86.62 (Mar 23) to 88.85, marking an increase of 2.23.
For Price / BV (X), as of Mar 24, the value is 10.37. This value exceeds the healthy maximum of 3. It has increased from 7.36 (Mar 23) to 10.37, marking an increase of 3.01.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 11.08. This value exceeds the healthy maximum of 3. It has increased from 8.20 (Mar 23) to 11.08, marking an increase of 2.88.
For EarningsYield, as of Mar 24, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 23) which recorded 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Poly Medicure Ltd as of April 25, 2025 is: 3,191.84

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of April 25, 2025, Poly Medicure Ltd is Undervalued by 25.91% compared to the current share price 2,535.00

Intrinsic Value of Poly Medicure Ltd as of April 25, 2025 is: 3,753.56

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of April 25, 2025, Poly Medicure Ltd is Undervalued by 48.07% compared to the current share price 2,535.00

Last 5 Year EPS CAGR: 17.60%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 24.42%, which is a positive sign. The company has higher reserves (690.00 cr) compared to borrowings (125.15 cr), indicating strong financial stability. The company has shown consistent growth in sales (412.46 cr) and profit (155.54 cr) over the years.	The stock has a high average Working Capital Days of 83.25, which may not be favorable. The stock has a high average Cash Conversion Cycle of 145.83, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Poly Medicure Ltd:
1. Net Profit Margin: 18.58%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 23.42% (Industry Average ROCE: 15.32%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 17.56% (Industry Average ROE: 31.54%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 23.63
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.77
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 81.5 (Industry average Stock P/E: 26.46)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.11
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Poly Medicure Ltd. is a Public Limited Listed company incorporated on 30/03/1995 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L40300DL1995PLC066923 and registration number is 066923. Currently Company is involved in the business activities of Wholesale of pharmaceutical and medical goods. Company's Total Operating Revenue is Rs. 1307.25 Cr. and Equity Capital is Rs. 47.99 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Medical Equipment & Accessories	No. 232-B, 3rd Floor, New Delhi Delhi 110020	investorcare@polymedicure.com http://www.polymedicure.com

Management
Name	Position Held
Mr. Devendra Raj Mehta	Chairman
Mr. Himanshu Baid	Managing Director
Mr. Rishi Baid	Joint Managing Director
Mr. Jugal Kishore Baid	Non Executive Director
Mrs. Mukulika Baid	Non Executive Director
Mr. Alessandro Balboni	Non Executive Director
Dr. Shailendra Raj Mehta	Ind. Non-Executive Director
Dr. Ambrish Mithal	Ind. Non-Executive Director
Dr. Sandeep Bhargava	Ind. Non-Executive Director
Mr. Vimal Bhandari	Ind. Non-Executive Director
Mr. Amit Khosla	Ind. Non-Executive Director
Ms. Sonal Mattoo	Ind. Non-Executive Director

FAQ

What is the intrinsic value of Poly Medicure Ltd?

Poly Medicure Ltd's intrinsic value (as of 25 April 2025) is ₹3191.84 — 25.91% higher the current market price of 2,535.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 25,680 Cr. market cap, FY2025-2026 high/low of ₹3,358/1,563, reserves of 2,541 Cr, and liabilities of 3,052 Cr.

What is the Market Cap of Poly Medicure Ltd?

The Market Cap of Poly Medicure Ltd is 25,680 Cr..

What is the current Stock Price of Poly Medicure Ltd as on 25 April 2025?

The current stock price of Poly Medicure Ltd as on 25 April 2025 is 2,535.

What is the High / Low of Poly Medicure Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Poly Medicure Ltd stocks is ₹3,358/1,563.

What is the Stock P/E of Poly Medicure Ltd?

The Stock P/E of Poly Medicure Ltd is 81.5.

What is the Book Value of Poly Medicure Ltd?

The Book Value of Poly Medicure Ltd is 256.

What is the Dividend Yield of Poly Medicure Ltd?

The Dividend Yield of Poly Medicure Ltd is 0.12 %.

What is the ROCE of Poly Medicure Ltd?

The ROCE of Poly Medicure Ltd is 23.6 %.

What is the ROE of Poly Medicure Ltd?

The ROE of Poly Medicure Ltd is 19.1 %.

What is the Face Value of Poly Medicure Ltd?

The Face Value of Poly Medicure Ltd is 5.00.